{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:24:51Z","timestamp":1763101491139,"version":"3.45.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Tofacitinib is an oral Janus kinase (JAK) inhibitor initially used for the treatment of arthritis. It demonstrated to effectively induce and maintain remission in adults with inflammatory bowel disease (IBD). However, data on its safety and efficacy in children with ulcerative colitis (UC), particularly in children with comorbid arthropathy, remained limited. This study aimed to evaluate the safety and efficacy of tofacitinib in treating children with UC who also had comorbid arthropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study enrolling children with UC and comorbid arthropathy who received tofacitinib treatment at the Gastroenterology Department of the Children's Hospital of Fudan University from January 2018 to December 2024. All enrolled UC patients underwent blood tests, stool tests, and colonoscopies, with the Pediatric Ulcerative Colitis Activity Index (PUCAI) used to assess clinical indicators, clinical response, and clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 16 patients met the inclusion criteria, all of whom presented with comorbid arthropathy. The mean age at onset was 7.1\u2009\u00b1\u20093.7 years, with a mean body mass index (BMI) of 14.6\u2009\u00b1\u20092.0\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . All patients had previously failed biologic therapy with infliximab. The majority patients initiated tofacitinib treatment at a starting dose of 2.5\u2005mg twice daily (bid) and adjusted based on clinical response, with a maximum dose of 5\u2005mg bid. Fecal calprotectin and endoscopic scores decreased significantly by weeks 14, 21, and 30, while albumin and BMI levels increased (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). The mean PUCAI scores also demonstrated a significant decline. One patient (6.25%) achieved clinical response by week 7, nine (56.25%) by week 14, and five (31.25%) by week 21. Six patients (37.5%) achieved clinical remission by week 30.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provided promising evidence for the safety and efficacy of tofacitinib as part of the treatment regimen for children with UC complicated with arthropathy. Further large-scale, prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1643668","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:22:30Z","timestamp":1763101350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of tofacitinib in children with ulcerative colitis complicated with arthropathy: a single-center study"],"prefix":"10.3389","volume":"13","author":[{"given":"Shijian","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"829040","DOI":"10.1155\/2013\/829040","article-title":"Highlights in IBD epidemiology and its natural history in the paediatric age","volume":"2013","author":"Gasparetto","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical presentation of Crohn\u2019s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes","volume":"26","author":"Yu","year":"2017","journal-title":"Semin Pediatr Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"691480","DOI":"10.3389\/fimmu.2021.691480","article-title":"Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice","volume":"12","author":"Bruscoli","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/apt.15496","article-title":"Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease","volume":"50","author":"Dolinger","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/rheumatology\/kev353","article-title":"Finding specific 10-joint juvenile arthritis disease activity score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study","volume":"55","author":"Backstr\u00f6m","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"otab075","DOI":"10.1093\/crocol\/otab075","article-title":"Tofacitinib adherence and outcomes in refractory inflammatory bowel disease","volume":"3","author":"Wiles","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1097\/MPG.0000000000003190","article-title":"Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease","volume":"73","author":"Moore","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/ard-2023-225094","article-title":"Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study","volume":"83","author":"Brunner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"10.5455\/apr.102920121510","DOI":"10.5455\/apr.102920121510","article-title":"Enthesitis is an extraintestinal manifestation of pediatric inflammatory bowel disease","volume":"1","author":"Horton","year":"2012","journal-title":"Ann Paediatr Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.intimp.2022.108517","article-title":"Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: a literature review","volume":"105","author":"Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1007\/s12325-019-01037-x","article-title":"Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel diseases","volume":"36","author":"Moran","year":"2019","journal-title":"Adv Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14309\/ajg.0000000000002485","article-title":"A review of available medical therapies to treat moderate-to-severe inflammatory bowel disease","volume":"119","author":"Chang","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/ibd\/izaa258","article-title":"Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease","volume":"27","author":"Sinh","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","article-title":"Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program","volume":"29","author":"Lichtenstein","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.12968\/hosp.1999.60.1.1019","article-title":"Novel treatments in inflammatory bowel disease","volume":"60","author":"Pathmakanthan","year":"1999","journal-title":"Hosp Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e31757","DOI":"10.1097\/MD.0000000000031757","article-title":"Japanese Pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with tofacitinib: a case report","volume":"101","author":"Kakiuchi","year":"2022","journal-title":"Medicine (Baltimore)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1643668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:22:31Z","timestamp":1763101351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1643668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":25,"alternative-id":["10.3389\/fped.2025.1643668"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1643668","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1643668"}}